Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ga-68 DOTATOC PET-CT in Neuroendocrine Tumors
NCT02441062Phase 2Completed
- Start
- Sep 2015
- Primary completion
- Jan 2020
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gallium Ga 68-edotreotide in Neuroendocrine Neoplasm (NEN), Carcinoid Tumor (CT), neuroblastoma and 3 more. Primary endpoint: Number of Participants With a Change in Treatment Management Based on Findings of the Gallium Ga 68-edotreotide PET/CT Scan at 36 months. Started Sep 2015; status: completed.
02
Drugs
gallium Ga 68-edotreotide
03
Conditions
Neuroendocrine Neoplasm (NEN)Carcinoid Tumor (CT)neuroblastomamedulloblastomaEwing sarcoma
Beyond the preview
Go deeper on NCT02441062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02441062.